These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

686 related items for PubMed ID: 17713153

  • 1. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M, Staszewski S, Doerr HW.
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [Abstract] [Full Text] [Related]

  • 2. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM, Bonjoch A, Iribarren J, Galindo MJ, Negredo E, Domingo P, Pérez-Alvarez N, Martinez-Picado J, Schapiro J, Clotet B, HIV Conference Call Study Group.
    HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
    [Abstract] [Full Text] [Related]

  • 3. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.
    Antivir Ther; 2006 Aug; 11(6):827-30. PubMed ID: 17310827
    [Abstract] [Full Text] [Related]

  • 4. Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
    Balestre E, Dupon M, Capdepont S, Thiébaut R, Boucher S, Fleury H, Dabis F, Masquelier B, GECSA.
    J Clin Virol; 2006 Jun; 36(2):95-9. PubMed ID: 16556509
    [Abstract] [Full Text] [Related]

  • 5. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
    Stephan C, Dauer B, Khaykin P, Stuermer M, Gute P, Klauke S, Staszewski S.
    Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129
    [Abstract] [Full Text] [Related]

  • 6. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND, Bader J, Lejone TI, Ringera I, Puga D, Glass TR, Klimkait T.
    Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
    [Abstract] [Full Text] [Related]

  • 7. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Perno CF, Ceccherini-Silberstein F, Mussini C.
    HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
    [Abstract] [Full Text] [Related]

  • 8. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS, HEAT Study Team.
    AIDS; 2009 Jul 31; 23(12):1547-56. PubMed ID: 19542866
    [Abstract] [Full Text] [Related]

  • 9. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R, Calza L.
    AIDS Patient Care STDS; 2008 Apr 31; 22(4):279-90. PubMed ID: 18290748
    [Abstract] [Full Text] [Related]

  • 10. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
    Moyle G, Higgs C, Teague A, Mandalia S, Nelson M, Johnson M, Fisher M, Gazzard B.
    Antivir Ther; 2006 Apr 31; 11(1):73-8. PubMed ID: 16518962
    [Abstract] [Full Text] [Related]

  • 11. Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
    Ferrer E, Gatell JM, Sanchez P, Domingo P, Puig T, Niubo J, Cortes C, Veloso S, Pedrol E, Leon A, Gutierrez M, Podzamczer D.
    AIDS Res Hum Retroviruses; 2008 Jul 31; 24(7):931-4. PubMed ID: 18671476
    [Abstract] [Full Text] [Related]

  • 12. Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.
    Mastroianni CM, d'Ettorre G, Vullo V.
    Expert Opin Pharmacother; 2006 Nov 31; 7(16):2233-41. PubMed ID: 17059380
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
    Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G, Ladisa N, Zazzi M, Trezzi M, Cicconi P, Corsi P, Nasta P, Cauda R, De Luca A, UCSC cohort, MASTER cohort, ARCA cohort.
    Infection; 2009 Oct 31; 37(5):438-44. PubMed ID: 19669091
    [Abstract] [Full Text] [Related]

  • 14. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS, ESS30009 Study.
    J Infect Dis; 2005 Dec 01; 192(11):1921-30. PubMed ID: 16267763
    [Abstract] [Full Text] [Related]

  • 15. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
    Kuritzkes DR.
    J Infect Dis; 2005 Dec 01; 192(11):1867-8. PubMed ID: 16267755
    [No Abstract] [Full Text] [Related]

  • 16. Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
    Kagan RM, Lee TS, Ross L, Lloyd RM, Lewinski MA, Potts SJ.
    Antiviral Res; 2007 Sep 01; 75(3):210-8. PubMed ID: 17442410
    [Abstract] [Full Text] [Related]

  • 17. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M, Opravil M, von Wyl V, Hirschel B, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Battegay M, Yerly S, Günthard H, Bucher HC, Swiss HIV Cohort Study.
    AIDS; 2007 Oct 18; 21(16):2201-7. PubMed ID: 18090047
    [Abstract] [Full Text] [Related]

  • 18. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A, Sawyer W.
    HIV Med; 2009 Oct 18; 10(9):527-35. PubMed ID: 19785663
    [Abstract] [Full Text] [Related]

  • 19. Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.
    Maggiolo F, Callegaro A, Arici C, Quinzan G, Gregis G, Ripamonti D, Tebaldi A, Goglio A, Suter F.
    Antivir Ther; 2003 Apr 18; 8(2):121-6. PubMed ID: 12741624
    [Abstract] [Full Text] [Related]

  • 20. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
    Descamps D, Ait-Khaled M, Craig C, Delarue S, Damond F, Collin G, Brun-Vézinet F.
    Antivir Ther; 2006 Apr 18; 11(6):701-5. PubMed ID: 17310814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.